#1 Clinical Trials Search in Europe

Opevesostat

Opevesostat (MK-5684) is an experimental drug being studied in clinical trials for the treatment of metastatic castration-resistant prostate cancer (mCRPC). These trials aim to evaluate the safety, efficacy, and pharmacokinetics of opevesostat alone and in combination with other therapies in patients who have progressed on previous treatments. The studies span different phases and compare opevesostat to existing therapies like abiraterone and enzalutamide.

Table of Contents

What is Opevesostat?

Opevesostat, also known as MK-5684, is a new experimental drug being developed to treat advanced prostate cancer[1]. It is specifically designed for patients with metastatic castration-resistant prostate cancer (mCRPC), which is a type of prostate cancer that has spread to other parts of the body and no longer responds to hormone therapy that lowers testosterone levels[5].

How Does Opevesostat Work?

While the exact mechanism of action is not fully described in the provided clinical trial information, Opevesostat appears to be a novel type of hormone therapy for prostate cancer. It likely works by targeting and inhibiting the androgen receptor or related pathways that drive prostate cancer growth[6]. This makes it different from traditional hormone therapies that focus on lowering testosterone levels.

What Conditions Does Opevesostat Treat?

Opevesostat is being developed specifically for:

  • Metastatic Castration-Resistant Prostate Cancer (mCRPC): This is an advanced form of prostate cancer that has spread beyond the prostate to other parts of the body (metastasized) and continues to grow despite treatments that lower testosterone levels[1].
  • Prostate Cancer that has progressed after other treatments: Particularly, it’s being studied in patients whose cancer has continued to grow after trying other newer hormone therapies (called next-generation hormonal agents or NHAs) and chemotherapy[5].

Clinical Trials and Research

Opevesostat is currently being studied in several clinical trials:

  • Phase 1 studies: These early studies are looking at the safety of Opevesostat, how it’s processed by the body (pharmacokinetics), and what doses might be appropriate[1][2].
  • Phase 3 studies: These larger studies are comparing Opevesostat to existing treatments like abiraterone acetate or enzalutamide to see if it’s more effective at prolonging survival and slowing cancer progression[5][6].
  • Combination studies: Researchers are also looking at combining Opevesostat with other cancer treatments like olaparib, docetaxel, or cabazitaxel to see if these combinations are more effective[4].

How is Opevesostat Administered?

Based on the clinical trial information:

  • Opevesostat is taken as an oral tablet, typically 5 mg twice daily[1].
  • It is usually given along with other medications:
    • Dexamethasone (1.5 mg once daily)
    • Fludrocortisone acetate (0.1 mg once daily)
  • Hydrocortisone may also be provided as a “rescue medication” if needed[5].

These additional medications are likely given to help manage side effects or replace hormones that Opevesostat might affect.

Side Effects and Safety

As Opevesostat is still in clinical trials, its full safety profile is not yet known. The trials are closely monitoring for side effects, which they call “adverse events” (AEs). Some things to note:

  • Researchers are tracking how many patients experience side effects and how many have to stop treatment due to side effects[1].
  • They’re paying special attention to serious side effects, which they call “dose-limiting toxicities” (DLTs)[4].
  • The use of steroid medications (dexamethasone, fludrocortisone, hydrocortisone) along with Opevesostat suggests that it may affect the body’s hormone levels, which could lead to side effects[5].

Patients in clinical trials are closely monitored for any potential side effects.

Comparison to Other Treatments

Several of the clinical trials are directly comparing Opevesostat to existing prostate cancer treatments:

  • Abiraterone acetate (brand names Zytiga, Yonsa): A hormone therapy that works by blocking an enzyme involved in testosterone production[5].
  • Enzalutamide (brand name Xtandi): Another hormone therapy that blocks the effects of testosterone on prostate cancer cells[6].

These comparisons will help determine if Opevesostat is more effective or has fewer side effects than current treatments.

Future Prospects

The development of Opevesostat represents an exciting potential new option for patients with advanced prostate cancer. If the clinical trials show positive results, it could provide a new treatment for patients whose cancer has stopped responding to other therapies.

Key things researchers are looking at include:

  • Whether Opevesostat can help patients live longer (overall survival)[5].
  • If it can slow down cancer growth better than existing treatments (progression-free survival)[6].
  • Its effect on quality of life and pain levels for patients[6].
  • How well it works in patients with specific genetic mutations in their cancer cells[5].

It’s important to remember that while these studies are promising, Opevesostat is still an experimental drug. More research is needed before it might become available as a standard treatment option.

Aspect Details
Drug Name Opevesostat (MK-5684)
Condition Studied Metastatic castration-resistant prostate cancer (mCRPC)
Trial Phases Phase 1, 2, and 3
Administration Oral tablet, typically 5 mg twice daily
Comparators Abiraterone acetate, Enzalutamide
Key Outcomes Measured Overall survival, Radiographic progression-free survival, PSA response, Objective response rate, Safety/adverse events
Patient Population mCRPC patients previously treated with next-generation hormonal agents and/or taxane-based chemotherapy
Combination Therapies Studied alone and in combination with other drugs (e.g., olaparib, docetaxel, cabazitaxel)
Biomarkers Androgen receptor ligand binding domain (AR LBD) mutations
Quality of Life Measures FACT-G questionnaire, pain progression

FAQ

  • What is opevesostat? Opevesostat (also known as MK-5684) is an experimental drug being studied as a potential new treatment for metastatic castration-resistant prostate cancer (mCRPC). It is taken orally as a tablet.
  • What type of prostate cancer is opevesostat being tested for? Opevesostat is being studied specifically for metastatic castration-resistant prostate cancer (mCRPC). This is an advanced form of prostate cancer that has spread beyond the prostate and no longer responds to hormone therapy that lowers testosterone.
  • How is opevesostat given to patients in clinical trials? In the clinical trials, opevesostat is typically given as a 5 mg oral tablet taken twice daily. It is often given along with other medications like dexamethasone and fludrocortisone acetate.
  • What are some of the main outcomes being measured in the opevesostat trials? Key outcomes being measured include overall survival, radiographic progression-free survival, prostate-specific antigen (PSA) response, objective response rate, and safety/side effects. The trials are also looking at quality of life measures and how long it takes for the cancer to progress.
  • How does opevesostat compare to existing prostate cancer treatments in the trials? Some of the phase 3 trials are comparing opevesostat to existing treatments like abiraterone acetate and enzalutamide in patients with mCRPC. The studies aim to determine if opevesostat is superior to these current therapies in terms of survival and delaying cancer progression.

Ongoing Clinical Trials on Opevesostat

  • Study of ODM-208 (opevesostat) safety and effectiveness in patients with metastatic castration-resistant prostate cancer

    Not recruiting

    1 1 1
    Investigated drugs:
    Finland France

Glossary

  • Metastatic castration-resistant prostate cancer (mCRPC): An advanced form of prostate cancer that has spread beyond the prostate to other parts of the body and no longer responds to treatments that lower testosterone levels.
  • Opevesostat: An experimental drug (also known as MK-5684) being studied as a potential new treatment for metastatic castration-resistant prostate cancer.
  • Pharmacokinetics: The study of how a drug moves through the body, including how it is absorbed, distributed, metabolized, and excreted.
  • Overall survival (OS): The length of time from the start of treatment until death from any cause. This is an important measure of how effective a cancer treatment is.
  • Radiographic progression-free survival (rPFS): The length of time during and after treatment that a patient lives without the cancer growing or spreading, as assessed by imaging scans.
  • Prostate-specific antigen (PSA): A protein produced by the prostate gland. PSA levels in the blood can be used to help detect prostate cancer and monitor treatment response.
  • Objective response rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment.
  • Adverse event (AE): Any unfavorable and unintended sign, symptom, or disease associated with the use of a medical treatment.
  • Blinded Independent Central Review (BICR): A method where treatment outcomes are assessed by expert reviewers who do not know which treatment each patient received, to help ensure unbiased results.
  • Next-generation hormonal agent (NHA): Newer hormone therapies used to treat prostate cancer, such as abiraterone and enzalutamide.
  • Androgen receptor ligand binding domain (AR LBD): The part of the androgen receptor where hormones like testosterone bind. Mutations in this area can affect how prostate cancer responds to treatment.
  • Hormone replacement therapy (HRT): In the context of these trials, HRT refers to medications given to replace hormones suppressed by the cancer treatment, such as dexamethasone and fludrocortisone.

References